Key Takeaways
- FY23 guidance raised to 55–60% revenue growth: Management lifted its outlook from 45–50% last quarter, citing supply chain planning, order book visibility and a diversified pipeline; it sees no downside to the new range.
- Margins reset by deliberate talent investment: EBITDA margin fell to 30% in FY22 as 1.2–1.4 points of EBITDA went to hiring ahead of time for new capabilities; employee cost as a share of revenue is expected to decline from 22% to 15–17% as revenues scale.
- Bloom relationship deepening fast: Sheet metal, enclosures and fueling assemblies all moved into qualification or production orders, adding a combined ~\$12–13 mn of new addressable revenue on top of the existing ₹288 Cr hot box order book.
- Electrolysers framed as the next big vertical: Management sees the electrolyser opportunity as potentially larger than Yuma and Keeylocko combined, with a real surge expected from FY2024.
- What to watch next quarter: Whether the ₹60 Cr+ nuclear L1 order converts in Q1, the pace of Bloom’s sheet metal and enclosure ramp updates promised in July, and any new customer additions from IAI, Elta and Enercon engagements.
Revenue Growth & Guidance
- FY22 performance: Revenue grew 30.7% YoY to ₹322 Cr, hitting the revised upward guidance of 30–35% despite COVID-19 disruptions and year-end geopolitical concerns.
- FY23 guidance raised: Management guided 55–60% revenue growth for FY23, up from 45–50% last quarter, after a detailed two-month review of supply chain, order book and emerging requirements.
- Confidence anchored in track record: The company has never revised guidance downward; last year it revised upward in the latter part of the year, and management states it sees no downside to the current 55–60% range.
- Order book target: The company expects to close FY23 with an order book of approximately ₹1,000 Cr, with FY23 order inflow guided at ₹800–850 Cr.
- Domestic segment doubling: Other segmental revenue (non-Yuma domestic) is expected to nearly double to ~₹200 Cr in FY23 from ~₹120 Cr, contributing meaningfully to diversification.
- Nuclear revenue visibility: ₹80–90 Cr of nuclear revenue is already under execution from orders on hand, with potential to reach ₹100 Cr; no new nuclear orders are factored into the current year’s execution plan.
Srinivas Reddy: "giving a revenue guidance of 55% to 60% overall is what we strongly feel is the right guidance and we do not see any kind of downside to this question."
Bloom Energy: Deepening & Diversification
- Hot box order book: The ₹288 Cr Bloom order book (as of December 2021) will be fully executed in FY23, with further orders expected during the year.
- Sheet metal qualification complete: The Adibatla sheet metal plant is fully operational and qualified for all 67 Bloom assemblies; production orders of ~\$2 mn plus have been released, with a further \$3 mn order for various assemblies post-qualification.
- Enclosures entering production: Three enclosure essays are under qualification, and an order for ~\$3 mn (700 units) has been received post-qualification; ramp-up will be step-by-step, with enclosures needed across all hot box variants.
- Fueling assembly upside: Prototypes have been submitted to Bloom for qualification, expected by June; management sees a major upside of ~\$7–8 mn and ₹60–70 Cr of revenue from this product alone.
- Market share gain potential: MTAR currently holds a 70:30 share versus a Taiwanese supplier; management expects this could move to 80:20, with clarity expected in July.
- Pricing discipline maintained: The company does not reduce price based on volume, only through innovation, while protecting margins; management states it has crossed the stage where volume-based discounting applies.
Srinivas Reddy: "we never reduce the price based on volume it is only based on innovation I have mentioned very clearly but we still try to maintain our margins every time so we are trying to do that moving forward as well so there is no question of reducing the price based on the volume because we have crossed that stage"
Margins: Reset & Recovery Path
- FY22 margin decline explained: EBITDA margin fell to 30% from 34% in FY21, primarily because ~1.2% to 1.4% of EBITDA (₹5.5-6 Cr) was invested in hiring talent ahead of time for new capabilities; increments and variable pay of ~₹3 Cr for key employees added further pressure.
- Operating leverage thesis: Employee benefit expenses as a percentage of revenue stood at 22% in FY22 and are expected to decline to 15–17% as revenues scale, providing a clear path to margin recovery.
- FY23 margin guidance: Management guided to ~30% EBITDA margin with ±100 bps, while signaling conservatism: it believes it can "probably do much better" but prefers to stick to an achievable number.
- FY24 margin outlook: Management expects overhead absorption to improve as revenues grow, with margins improving "better and better"; revenue growth in FY24 is expected to be "more or less similar" to FY23.
- R&D intensity stable: R&D sales increased to 36% of revenue in FY22 versus ~34% in the prior three years, attributed to product mix rather than a structural shift.
Srinivas Reddy: "normally I would like to say currently also we will do 30% probably we might do much better than that but it is always better to stick to a number which we can probably achieve and it is always better that is what I strongly believe in"
Electrolysers & Clean Energy Expansion
- Electrolysers positioned as a third vertical: Management sees the electrolyser opportunity as potentially larger than both Yuma and Keeylocko; it will be treated as an independent vertical going forward.
- Prototype to batch production: The electrolyser prototype has been approved, and batch production of 60 units is now underway; the real surge in numbers is expected from FY2024.
- Bellows indigenization complete: Bellows manufacturing, previously imported from the US for clean energy applications, has been fully localized in-house, a major achievement in innovation and import substitution.
- Keeylocko progress: The first 30 Keeylocko units were dispatched in Q4; prototypes were manufactured, airlifted, and returned with excellent feedback on quality; the process will start from H2 FY23, though management is not yet planning for a large Keeylocko number.
- Yuma order visibility: 4,100 Yuma units are on order for the calendar year; the next calendar year order will be discussed in July and is expected to be "definitely much higher."
Srinivas Reddy: "this vertical we are really looking forward to it from FY2024 in a very big way, which can be even bigger than Yuma and Keeylocko itself"
New Capabilities & Customer Diversification
- Roller screws qualified: MTAR qualified for roller screws, a 100% import substitute previously sourced from Rollvis of Sweden; first articles are being delivered to DRDO in Q1 FY23.
- Electromechanical actuators: The company has started developing electromechanical actuators and received orders of ~₹7.5 Cr, under execution in FY23.
- Semi-cryo engine milestone: The semi-cryo engine for higher-payload GSLV launches (enhancing capacity from 4 tons to 6 tons) is expected to be released in Q3 FY23, the first such engine manufactured in the country.
- New customer qualifications passed: Worldwide (specialized ball screws), Hitachi, Bental, ARDE, DMDE, GE-Hydro, Voith and Andritz have all passed the qualification stage and are executing orders; Israel Aerospace Industries and Elta are visiting next week with interest in electronics and SMEs.
- Gee Pee Aerospace acquisition: The acquisition is expected to close by end of May or early June 2022, providing MSME advantages for domestic orders and offset clause benefits with MNC customers; the unit will be ramped up quickly as a subsidiary.
- System-level ambition: Management’s vision is to move into system-level integration within a year, starting with integrating hot boxes into enclosures with fully integrated electronic systems, which would reduce Bloom’s logistics costs and increase MTAR’s value add.
Srinivas Reddy: "we are going to move into the system level itself moving forward in a year's time and that is where you really take the company to a completely different level"
Working Capital & Balance Sheet
- Working capital days rose sharply: Working capital days increased from 198 to 299 days, driven by raw material inventory rising to 88 days (advance procurement to avoid production stoppages from COVID-19 and geopolitical concerns), WIP rising to 121 days (higher manufacturing based on orders), and receivables rising to 167 days.
- Receivables quality intact: 95% of receivables are current and not overdue; the increase was driven by major March shipments to Bloom and NPCL; all money is expected by the end of the current quarter with no bad debt concerns.
- Bloom payment terms: Bloom receivables are taking 110 days versus 45-day contractual terms due to supply chain disruptions on their side.
- Inventory strategy deliberate: The company built raw material inventory anticipating continued commodity price spikes; spot buys are 30–40% higher, so advance purchasing kept production lines active and avoided raw material cost impact.
- Domestic advances provide cushion: Domestic customers provide advances totaling ~30% of order value, staggered across order placement, engineering document submission and raw material receipt.
- Factoring exploration: The company is exploring non-recourse factoring with foreign banks (Japanese banks and others) to take receivables off the balance sheet; this is not currently available in India, where only recourse factoring exists.
- ROCE decline tied to capex: ROCE fell from 19% to 14% because of ongoing capex investment at the Adibatla unit for future revenue growth; absolute numbers increased YoY, and return ratios are expected to improve as revenues scale.
Srinivas Reddy: "Today if you do a spot buy of any raw material it is 30% to 40% higher and it is ridiculous so we have planned this year ahead of time like last year fortunately we have anticipated even for this year that things might continue in a similar manner and stabilize probably six months from now or by end of December"
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 55–60% YoY growth for FY23 | FY23 full year |
| EBITDA margin | ~30% with ±100 bps | FY23 full year |
| Order book | Close FY23 with ~₹1,000 Cr order book | FY23 year-end |
| Order inflow | ₹800–850 Cr of new orders | FY23 full year |
| Nuclear L1 order conversion | Additional ₹60 Cr+ nuclear order (already L1) | Q1 FY23 |
| Employee cost ratio | Decline from 22% of revenue to 15–17% | FY23 |
| Bloom fueling assembly qualification | Qualification expected from Bloom | June 2022 |
| Gee Pee Aerospace acquisition close | Transaction closure and ramp-up as subsidiary | End of May / early June 2022 |
| Semi-cryo engine release | First such engine manufactured in India | Q3 FY23 |
| Electrolysers surge | Real surge in numbers, treated as independent vertical | FY2024 |
| System-level integration | Move into system-level for all customers | Within a year |
| Raw material price stabilization | Prices expected to stabilize | By end of December 2022 |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue | ₹98.6 cr, +26.2% QoQ from ₹78.1 cr in Q3 FY22 |
| FY22 annual revenue | ₹322 cr, +30.7% YoY |
| EBITDA | ₹27.7 cr, +21.4% QoQ from ₹22.8 cr in Q3 FY22 |
| FY22 annual EBITDA | ₹94.4 cr, +13.6% YoY |
| EBITDA margin | ~30% for FY22, down from 34% in FY21; ~1.5 ppt impact from employee benefit expenses for future growth hiring |
| Profit after tax | ₹19.8 cr, +48.8% QoQ from ₹13.3 cr in Q3 FY22 |
| FY22 annual PAT | ₹60.9 cr, +32.1% YoY |
| Diluted EPS | ₹6.4 vs ₹4.3 in Q3 FY22 |
| FY23 revenue growth guidance | 55% to 60% |
| FY23 EBITDA margin guidance | ~30% with ±100 bps |
| Order book | ₹648.8 cr as of March 31, 2022; additional ₹60 cr+ nuclear order expected in Q1 FY23 with L1 declared |
| Order book composition | 25% nuclear, 28% space & defence, 45% clean energy, rest ~₹9.56 cr in various products |
| FY23 order inflow guidance | ₹800 to ₹850 cr; expected to close FY23 with ~₹1,000 cr order book |
| ROCE | 14% as of March 2022 vs 19%, decrease due to capex investment at Adibatla unit |
| Working capital days | 299 days vs 198 days; raw material inventory 88 days, WIP 121 days, receivables 167 days |
| Employee benefit expenses as % of revenue | 22% in FY22, expected to decline to 15%–17% in FY23 |